These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 24367063)

  • 21. Health Literacy and Health Care Utilization in Austria.
    Kvas A; Kvas G
    Health Lit Res Pract; 2023 Oct; 7(4):e197-e206. PubMed ID: 37935383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of Inadequate Health Literacy among Patients with Type 2 Diabetes Mellitus: Assessment with Different Self-Reported Instruments.
    Levic M; Bogavac-Stanojevic N; Lakic D; Krajnovic D
    Int J Environ Res Public Health; 2023 Mar; 20(6):. PubMed ID: 36982101
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Glycemic Control of a Pharmacist-Led Medication Management Program in Patients with Type 2 Diabetes.
    Ko JJ; Lu J; Rascati K; Stock EM; Juan J; Suh K; Kim Y; Tabor PA; Godley PJ
    J Manag Care Spec Pharm; 2016 Jan; 22(1):32-7. PubMed ID: 27015049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Direct health care costs in patients with type 2 diabetes mellitus six months after starting insulin treatment in Spain: the INSTIGATE study].
    Costi M; Smith H; Reviriego J; Castell C; Goday A; Dilla T
    Endocrinol Nutr; 2011; 58(6):274-82. PubMed ID: 21641287
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
    Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C; Axon DR; Mollon L; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
    [No Abstract]   [Full Text] [Related]  

  • 28. Healthcare resource utilization and costs assessment of type 2 diabetes patients initiating exenatide BID or glargine: a retrospective database analysis.
    Pawaskar M; Zagar A; Sugihara T; Shi L
    J Med Econ; 2011; 14(1):16-27. PubMed ID: 21158486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficiency of the Austrian disease management program for diabetes mellitus type 2: a historic cohort study based on health insurance provider's routine data.
    Ostermann H; Hoess V; Mueller M
    BMC Public Health; 2012 Jun; 12():490. PubMed ID: 22742209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
    Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
    J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with increased healthcare costs in Medicare Advantage patients with type 2 diabetes enrolled in a large representative health insurance plan in the US.
    Slabaugh SL; Curtis BH; Clore G; Fu H; Schuster DP
    J Med Econ; 2015 Feb; 18(2):106-12. PubMed ID: 25333214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early discontinuation and related treatment costs after initiation of Basal insulin in type 2 diabetes patients: a German primary care database analysis.
    Anderten H; Dippel FW; Kostev K
    J Diabetes Sci Technol; 2015 May; 9(3):644-50. PubMed ID: 25573957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utilization patterns of insulin therapy and healthcare services among Japanese insulin initiators during their first year: a descriptive analysis of administrative hospital data.
    Ikeda S; Crawford B; Sato M
    BMC Health Serv Res; 2016 Jan; 16():6. PubMed ID: 26759271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
    Bajpai S; Wong-Jacobson S; Liu D; Mitchell B; Haynes G; Syring K; Ali AK; Chinthammit C
    J Manag Care Spec Pharm; 2021 Mar; 27(3):385-391. PubMed ID: 33645242
    [No Abstract]   [Full Text] [Related]  

  • 38. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
    Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
    Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
    Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
    J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
    Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
    Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.